We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.07 | 4.58% | 1.60 | 651,628 | 16:35:15 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.60 | 1.80 | 1.70 | 1.70 | 1.70 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -1.16 | 4.67M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:15 | UT | 25,075 | 1.60 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 13/11/2023 | 07:00 | RNSNON | Evgen Pharma PLC Upcoming conferences |
| 31/10/2023 | 14:38 | ALNC |  TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings |
| 31/10/2023 | 07:00 | UKREG | Evgen Pharma PLC Half-year Report |
| 26/10/2023 | 06:00 | RNSNON | Evgen Pharma PLC Erasmus Medical Center begins glioblastoma studies |
| 19/10/2023 | 18:39 | ALNC | IN BRIEF: Evgen showcases importance of new enteric-coated formulation |
| 19/10/2023 | 13:26 | RNSNON | Evgen Pharma PLC Authored Article Publication |
| 05/9/2023 | 13:22 | ALNC | Evgen Pharma hires interim CFO from Faron, chair to retire this month |
| 05/9/2023 | 06:00 | UKREG | Evgen Pharma PLC Directorate Changes |
| 15/8/2023 | 09:01 | ALNC | Evgen Pharma says trial shows new SFX-01 drug formulation is safe |
| 15/8/2023 | 06:00 | UKREG | Evgen Pharma PLC Final Report from Phase 1b PK/PD study |
Evgen Pharma (EVG) Share Charts1 Year Evgen Pharma Chart |
|
1 Month Evgen Pharma Chart |
Intraday Evgen Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 29/11/2023 | 16:12 | EVGEN PHARMA - 2022 BREAST CANCER TREATMENT SFX-01 | 2,309 |
| 02/11/2022 | 19:21 | EVGEN PHARMA - Well funded - A respected BOD - A rising Star | 214 |
| 10/10/2022 | 17:41 | Evgen Pharma PLC | 48 |
| 10/10/2022 | 10:33 | Evgen Guild thread | 151 |
| 10/10/2022 | 06:20 | Evgen Pharma: Undoubted Transformational Upside Potential | 2,433 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:35:15 | 1.60 | 25,075 | 401.20 | UT |
| 16:00:39 | 1.78 | 150,000 | 2,670.00 | O |
| 16:00:09 | 1.78 | 35,000 | 623.00 | O |
| 14:16:35 | 1.79 | 55,000 | 981.75 | O |
| 14:08:51 | 1.78 | 150,000 | 2,670.00 | O |
| Top Posts |
|---|
Posted at 29/11/2023 08:20 by Evgen Pharma Daily Update Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 1.53p.Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £4,673,098. Evgen Pharma has a price to earnings ratio (PE ratio) of -1.16. This morning EVG shares opened at 1.70p |
Posted at 15/11/2023 21:43 by kingalf Are you lot delusional, if someone was building a position in these the price wouldn't keep dropping. I just find it incredibly strange how a positive narrative can be added to a falling share price. |
Posted at 19/10/2023 13:35 by manual dexterity Evgen Pharma PLC19 October 2023 Evgen Pharma plc ("Evgen" or the "Company") Authored Article on Enteric Coating Formula Alderley Park, UK - 19 October 2023: Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines for the treatment of cancer and other indications, highlights an article published today in respected industry publication The Medicine Maker, authored by Evgen's Chief Business Officer, Dr Helen Kuhlman. The article, entitled The Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01. The Medicine Maker is an online and print publication based in the United States, focusing on the entire spectrum of drug development and with a readership of pharmaceutical industry professionals across all levels. The article can be read online here. -Ends- |
Posted at 10/10/2023 09:49 by kingalf Even lower today, 1.849 offer for 10k.Huw clearly has Viking heritage, he and his fellow board members have definitely pillaged Evgen. The ratio of input (salaries) to output (share price) is boardering on the criminal in my eyes. Still they can't buy for legal reasons, can't wait to see what that advice was and who gave it to them. |
Posted at 30/8/2023 21:38 by clocktower Just thought I would double check hat and took the following from the report:“ Share options may be granted under the LTIP as follows: ï An initial award to Executive Directors on joining the Company to support the recruitment and drive retention. ï An annual award to Executive Directors and other staff members to be made around the time of the AGM, though this may be deferred in the event of staff having inside information. Since 2021 vesting of share options has been subject to; a shareholder return metric (30%), delivery of strategic corporate objectives (40%), and time-vesting 3 years from grant (30%). The aims of this structure are to continue to align senior management remuneration with shareholder returns and to support staff retention. Achievement of the shareholder return metric depends on absolute share price performance. For the 2022/23 year grants, if the share price is between 8p and 38p (based on the non-volume weighted mean average price over the 3 months preceding the vesting date), options will vest on a straight-line basis between nil and 100% of the 30% shareholder return metric. The 2021/22 year grants are similarly assessed, save that the share price range is between 12p and 38p. Details of the awards can be seen on page 27. |
Posted at 30/8/2023 20:10 by clocktower hat, although the last options were nil paid as far as I can recall, I am not so sure when you state they could potential be dilutive, as I thought there was a strike price that was above the current share price and some as high as 10p unless my memory is confused but it was all set out in the last full year accounts which are available online if anyone wants to check.Please correct me if I am wrong as I would not like to mislead or try to run the share price lower just to jump back in if I felt the news justified it. Usually there is a bit of insider buying just before major price changing news but that is yet to show its head. |
Posted at 04/8/2023 08:47 by hatfullofsky In conclusion, the administration of Ixaka Ltd, in which Evgen Pharma's CEO is a non-executive director, is a significant development that investors should pay attention to. It is recommended to closely follow any updates from Evgen Pharma regarding the potential impact of this situation on their business.Rockets ? Space shuttle Challanger more like Why are EVG putting the emphasis on the investor, rather than the companies mitigation actions, the statement above will suppress the share price until the issues are resolved. |
Posted at 26/7/2023 21:38 by clocktower Some of you were discussing the share options strike prices the other day, so I thought I would set out the figures from the last report.So I guess they will be doing everything in there power to reach these targets as some become exercisable from this October 2023. So impo these are so undervalued, with news due anytime, I expect them to rocket. "Since 2021 vesting of share options has been subject to; a shareholder return metric (30%), delivery of strategic corporate objectives (40%), and time-vesting 3 years from grant (30%). The aims of this structure are to continue to align senior management remuneration with shareholder returns and to support staff retention. Achievement of the shareholder return metric depends on absolute share price performance. For the 2022/23 year grants, if the share price is between 8p and 38p based on the non-volume weighted mean average price over the 3 months preceding the vesting date), options will vest on a straight-line basis between nil and 100% of the 30% shareholder return metric. The 2021/22 year grants are similarly assessed, save that the share price range is between 12p and 38p. Details of the awards together with outstanding options granted to the Executive Directors prior to Admission are set out in the Since 2021 vesting of share options has been subject to; a shareholder return metric (30%), delivery of strategic corporate objectives (40%), and time-vesting 3 years from grant (30%). The aims of this structure are to continue to align senior management remuneration with shareholder returns and to support staff retention. Achievement of the shareholder return metric depends on absolute share price performance. For the 2022/23 year grants, if the share price is between 8p and 38p (based on the non-volume weighted mean average price over the 3 months preceding the vesting date), options will vest on a straight-line basis between nil and 100% of the 30% shareholder return metric. The 2021/22 year grants are similarly assessed, save that the share price range is between 12p and 38p. Details of the awards together with outstanding options granted to the Executive Directors prior to Admission are set out in the table. Page 27. |
Posted at 19/6/2023 06:08 by manual dexterity Evgen Pharma PLC Grant Success for Glioblastoma studies19/06/2023 7:00am UK Regulatory (RNS & others) Evgen Pharma (LSE:EVG) Intraday Stock Chart Monday 19 June 2023 Click Here for more Evgen Pharma Charts. TIDMEVG RNS Number : 0732D Evgen Pharma PLC 19 June 2023 Evgen Pharma plc ("Evgen" or "the Company" or "the Group") Evgen receives notification of grant success in the Netherlands for Glioblastoma Pre-clinical and Clinical Studies Grant provides non-dilutive funding for SFX-01 in glioblastoma 19 June 2023 - Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces that the Company's collaborator at The Erasmus University Medical Center, Rotterdam, NL has received a successful notice of a grant for Investigator Sponsored pre-clinical and clinical studies of SFX-01 in glioblastoma. The grant was awarded by KWF Dutch Cancer Society. The studies funded by the grant will cover use of SFX-01 in pre-clinical glioblastoma models, followed by a clinical Investigator Sponsored Study (ISS) window-of-opportunit Dr Huw Jones, CEO of Evgen Pharma said: "We announced earlier this year that our glioblastoma programme would be conducted as an ISS with non-dilutive funding. This award means that we remain on schedule to deliver this study in close collaboration with Dr Geurts. Congratulations to her and the Evgen team who compiled the grant application. The non-dilutive funding enables us to continue to preserve our capital and maintain our cash runway to the end of 2024 whilst continuing to generate valuable data on SFX-01. If the ISS and subsequent clinical trials succeed, SFX-01 will represent a novel and well tolerated option for patients with this devastating disease." Enquiries: Evgen Pharma plc Tel: +44 207 457 2020 Dr Huw Jones, CEO enquiries@evgen.com Richard Moulson, CFO FinnCap (Nominated Advisor and Tel: +44 20 7220 0500 Broker) Geoff Nash / Teddy Whiley (Corporate Finance) Alice Lane/Nigel Birks (ECM) Instinctif Partners Tel: +44 207 457 2020 Melanie Toyne-Sewell / Rozi Morris Evgen@Instinctif.com / Adam Loudon |
Posted at 14/6/2023 17:52 by clocktower Kingalf you have been posting for a long time about EVG, almost exclusively I notice.The company raised £11million in 2021 at 8p before the deal with Stalicla was done, they have also achieved other milestones, including Evgen's new SFX-01 tablet formulation. This has all come at a cost. There has also been other collaborations, like that with Manchester Breast Centre, Collaboration with Università Sapienza di Roma etc. in 2022. We now have the share price at less than half of that but having achieved a great deal, with more news due before to long. When they raised £11 million, they could have raised a lot more because, applications under the Excess Application Facility cannot be satisfied in full, applications for New Ordinary Shares under the Excess Application Facility will be scaled back in accordance with the terms set out in the Circular. (RNS March 2021). The company has now done a lot of the important costly work and still has circa £5 million - I find it amazing that you do not consider the share to be worth less than 50% of the price money was raised at, with a deal in the bag that is due to bring in very substantial milestone payments - having already received around $500,000 As regards another raise, you can plug that, as one cannot see into the future, as if needed it could well be done at a Premium to the current share price because of performance and results. I know you predicted a raise before the last one but it does not follow that because of the share price fall, which might be because of the market forces in general or a number of holders seeing the opportunity to sell and finding the share price falling giving them the chance to buy back in for less money or buy more shares. In fact as you know Wololol only today stated he was waiting for the share price to fall further so he could buy back in having sold a short time ago. You also know that if the directors started buying in any decent volume or there was positive news (that could still be preventing them from do so), the share price would likely shoot up in a flash, and possible leading to anyone like W from missing the first boat, so to speak. Of course there is risk but unless you cannot afford to take risks, maybe it would be better to put your money in managed funds or remain in cash in National Savings if you want reasonable security but still watch inflation eat into your nest egg. Just spread your investments and only invest in any one, what you can afford to loose. Like I suggested to W take a look at TRX 54/55p if you want something with lower risk and I maybe wrong but I have invested in it several times before, riding the waves, and it is once again on the way up. So if your a trader and waiting to buy lower, good luck but I am invested and I have been and still am buying trading shares, that I have openly declared - so take your pick and do what you believe in but I have a very substantial holding that is in the RED at this time - unfortunately but that is the risk I accept. So do investors either go with you and W or with markth126 and OnTarget and myself etc and buy or hang around watching and either wanting each of us to loose a lot of money or missing out yourselves. In front of my desk I have a framed picture containing Rudyard Kipling's poem "IF" so I remember not to fear losses but learn from them when I do. “If” by Rudyard Kipling If you can keep your head when all about you Are losing theirs and blaming it on you, If you can trust yourself when all men doubt you, But make allowance for their doubting too; If you can wait and not be tired by waiting, Or being lied about, don’t deal in lies, Or being hated, don’t give way to hating, And yet don’t look too good, nor talk too wise: If you can dream—and not make dreams your master; If you can think—and not make thoughts your aim; If you can meet with Triumph and Disaster And treat those two impostors just the same; If you can bear to hear the truth you’ve spoken Twisted by knaves to make a trap for fools, Or watch the things you gave your life to, broken, And stoop and build ’em up with worn-out tools: If you can make one heap of all your winnings And risk it on one turn of pitch-and-toss, And lose, and start again at your beginnings And never breathe a word about your loss; If you can force your heart and nerve and sinew To serve your turn long after they are gone, And so hold on when there is nothing in you Except the Will which says to them: ‘Hold on!’ If you can talk with crowds and keep your virtue, Or walk with Kings—nor lose the common touch, If neither foes nor loving friends can hurt you, If all men count with you, but none too much; If you can fill the unforgiving minute With sixty seconds’ worth of distance run, Yours is the Earth and everything that’s in it, And—which is more—you’ " |
Posted at 09/6/2023 08:05 by clocktower Post 1688 - Rinse and repeat.However, I will respond to a point or two in your post, as a holder and buyer of the stock. I have not invested here because of Knight - he clearly has received advice or has knowledge of the potential here to have taken such a large stake, much in the same way as I have done in this case but I would not invest well over one million but if I had a billion I might, as I was advised by someone with very considerable knowledge in the field to take a look and research for myself, as SFX‐01 has huge potential. Fortunately for myself I started buying at sub 5p a very small amount, I added considerable more at around 3.4p - on the second spike, having bought some trading stock after the first spike, as I expected it go higher and was confident of another spike and I then bought trading stock and when it spiked again I then top sliced when it did. I have added even more with the profits I made from the trading stock as I consider the deals done make the share very undervalued. The accounts are what was expected, so nothing to get upset about there. I now have the largest stake in EVG that I have ever held. When it spikes again (and I expect it will on the next expected news or another deal) I will top slice again at around 8p and rinse and repeat buying more stock with profits on the dip after that, as I believe like markth126, that we will see this trading maybe up between 30/50p in time maybe more. Very large holders are usually kept pretty well informed but some do not want to be insiders, as it prevents them trading, so K certainly would not be shouting from the rooftops at a time like this, when everything is going to plan. The market in general is holding the share price down I guess, nothing else or less. If you are a disgruntled investor, having seen the share price fall so far, I quite understand your position but on the other hand if your trying to suggest K should do what you would like, then you have no hope, as I have not even contacted H Jones myself, as I believe he has done a good job and pulled off good deals. The timing is on track imo, you cannot force partners to run to your tune, as they have their own interests as I suspect you do - maybe wanting the share price even lower to buy in - if that is the case good luck but I am still a buyer, and I even mentioned I bought another 60k yesterday, and I was buying before the results. My only gripe is the way they awarded themselves nil paid options and did not announce the targets that were set, this I believe is out of order, as I have said before but as it is not in their interests to benefit until the share price is much higher, there is nothing to worry about there for the time being. It may also be taken over well before it hits the 30/50p range, which will be a pity for investors impo but I expect the take out price to be well above 10p if it is soon. DYOR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
